Edited by
Beverly A. Teicher
Lee M. Ellis

2008

Angiogenesis as a therapeutic target for malignant disease has evolved from a pioneering idea outside of the mainstream of therapeutic development to an FDA-approved therapy widely used in patients with metastatic disease.